1 INTRODUCTION
==============

Cancers are complex diseases regulated by interactions of multiple signaling pathways interacting with each other. Though there are some anticancer drugs, they are often not curative and associated with acquired drug resistance. It is believed that a single drug can target only one disease signaling module, whereas alternative signaling pathways will be activated to maintain tumor development. For example, in melanoma, the selective BRAF inhibitor, PLX4032, can induce tumor responses in the majority of patients with BRAF V600E mutant melanoma, but the duration of this response is limited owing to the development of acquired resistance, which may be due to alternative pathways parallel to the 'BRAF-MEK-ERK' signaling pathway ([@btu278-B13]; [@btu278-B20]). To reduce the drug resistance effect, and improve cancer treatment outcomes, drug combinations are considered as an optimal option.

The ideal drug combinations expected by clinicians are combinations of Food and Drug Administration (FDA)-approved drugs or existing bioactive compounds that have entered clinical trials and passed safety tests. These drug combinations could be used by patients without toxic side effects. Drug combination prediction has been a challenging task in computational biology, despite a few studies in the area. The genetic algorithm was, for example, proposed to find the optimal combinations of a small number of drugs based on the experimental results ([@btu278-B30]). The method, however, is not able to identify optimal drug combinations from a large set of drugs, as it requires experimental validations in the prediction process. The machine learning-based approach was proposed to classify drugs into combinations based on molecular and pharmacological features of drugs ([@btu278-B28]). However, the features of drugs are too general to be informative, and the method does not integrate the rich genomic profiles of drugs and disease into consideration. Combinatorial Drug Assembler (CDA) was developed to identify drug combinations based on enrichment analysis of genomic profile data. However, the enrichment analysis implemented in the method is based on differentially expressed genes, disease driver genes are not clearly defined, so that drugs targeting the causal dysfunctional signaling modules of disease maybe missed out ([@btu278-B16]). To overcome the aforementioned problems, we propose a novel computational tool, DrugComboRanker, for predicting drug combinations targeting multiple signaling modules of cancer-specific networks through integrative analysis of genomic profiles of both drugs and cancers.

2 MATERIALS AND METHODS
=======================

2.1 Overview of DrugComboRanker
-------------------------------

This study seeks to answer a clinical question that which drugs can be combined with existing therapy to reduce drug resistance and improve patients' outcomes. We have thus developed a novel tool, DrugComboRanker, to prioritize drug combinations and uncover the underlying mechanisms of action. The approach is designed based on the following two observations. First, dysfunctional signaling networks of diseases are complex and stable, and effective drug combinations can inhibit major modules of the networks simultaneously. Second, drugs often have multiple active target genes or proteins. Grouping targets of drugs with similar transcriptional responses profiles allows better recovery of their targeted signaling modules in disease than based on individual targets alone. [Figure 1](#btu278-F1){ref-type="fig"} is an overview of the proposed DrugComboRanker. The drug functional network is firstly reconstructed based on genomic profiling data of drugs that are available in the Connectivity Map (CMAP) database. The Bayesian non-negative matrix factorization with the β-divergence (BNMFβD; [@btu278-B27]) approach is conducted to partition the drug functional network into connected functional communities, whose targets indicate the inhibited signaling modules of diseases. On the other hand, the dysfunctional signaling modules of diseases are reconstructed by integrating disease genomics data and protein interactome data. Drug combinations are then ranked from different drug functional communities, which inhibit disease signaling network modules. Fig. 1.Overview of the DrugComboRanker for prioritizing disease-specific drug combinations

2.2 Drug functional network reconstruction {#SEC2.2}
------------------------------------------

The aim of drug function network reconstruction is to identify drug communities that share common transcriptional responses to drug treatment. We reconstruct, the drug functional network based on the data of the CMAP (CMap, build 02; [@btu278-B15]), which consists of 6100 gene expression profiles of four cancer cell lines (MCF7, PC3, HL60 and SKMEL5) treated by 1309 drugs at different doses. We first combine the similarity metric proposed in ([@btu278-B11]) with the metric defined in the STITCH database ([@btu278-B14]) as a new drug similarity metric as follows. First, for each individual drug at each dose, genes are ranked based on their fold changes (drug treatment versus control). Then, gene rank lists at different doses are merged into one gene rank list by using a hierarchical majority voting scheme ([@btu278-B11]). The merging procedure first compares gene rank lists using the Spearman's Footrule similarity metric ([@btu278-B7]), and then the two most similar lists are merged repeatedly by using the Borda Merging strategy ([@btu278-B18]). Consequently, gene signatures for individual drugs are created by optimally selecting the top- and bottom-ranked 250 genes, respectively. This size of these signatures is heuristically determined as described in ([@btu278-B11]). Finally, the gene set enrichment analysis ([@btu278-B26]) score, $S_{G}\left( {i,j} \right)$, is used as the dissimilarity metric between drug *i* and drug *j*. A threshold *T* = 0.7848 (the third quantile of the empirical probability distribution of the drug dissimilarity metric) is given to remove the non-significant dissimilarities as follows: $$S_{G}^{'}\left( {i,j} \right) = \left\{ \begin{matrix}
{S_{G}\left( {i,j} \right),\operatorname{}\operatorname{}if S_{G}\left( {i,j} \right) \leq T} \\
{C,\qquad else} \\
\end{matrix} \right.$$ Then we convert the dissimilarity into the normalized similarity score, $S_{G}^{''}\left( {i,j} \right)$ as $S_{G}^{''}\left( {i,j} \right) = 1 - NORM\left( {S_{G}^{'}\left( {i,j} \right)} \right)$ and $NORM(S_{G}^{'}\left( {i,j} \right)) = (S_{G}^{'}\left( {i,j} \right) - \text{min}(S_{G}^{'}\left( {i,.} \right)))/(\text{max}(S_{G}^{'}\left( {i,.} \right)) - \text{min}(S_{G}^{'}\left( {i,.} \right)$ where $S_{G}^{'}\left( {i,.} \right) = \left\{ S_{G}^{'}\left( {i,1} \right), \right.$ $\left. S_{G}^{'}\left( {i,2} \right),\ldots,S_{G}^{'}\left( {i,n} \right) \right\}$ denotes all the connection scores linking to the i-th node. Here, we empirically set $C = 10$. In addition to the similarity of transcriptional responses, a different similarity metric, $S_{s}(i,j)$, was defined in STITCH database ([@btu278-B14]) by integrating a combined score of structure similarity, experimental similarity and text mining similarity score. The structure similarity is defined by the Tanimoto 2D chemical similarity scores ([@btu278-B19]). The experimental similarity is calculated by the Pearson correlation of the activity patterns of the compounds based on NCI60 screens. The text mining similarity is computed by mining the curated database, such as OMIM and MEDLINE, using a co-occurrence scheme and a natural language processing approach ([@btu278-B12]; [@btu278-B24]). In this study, we combine the two similarity metrics as $S\left( {i,j} \right) = S_{s}\left( {i,j} \right) + S_{G}^{''}(i,j)$. The rational to use the combined similarity is to generate better drug community structure when applying the clustering algorithm on the drug functional network. Finally, a drug functional network is reconstructed with 1308 nodes and 51 164 edges. [Figure 2](#btu278-F2){ref-type="fig"} shows an example of the reconstructed drug functional network community. Fig. 2.Snapshots of the drug functional network (top) and an example of the reconstructed drug network community (bottom)

2.3 Drug community discovery by using Bayesian non-negative matrix factorization with **β**-divergence {#SEC2.3}
------------------------------------------------------------------------------------------------------

Next, we partition the reconstructed drug functional network into communities (modules) within which drugs share common mechanisms of action (targeting the same or related signaling modules), as illustrated in [Figure 2](#btu278-F2){ref-type="fig"}. We use the BNMFβD ([@btu278-B27]) for the network partition. The algorithm has shown good partition results on various classes of real-world signals such as audio and images ([@btu278-B27]), Specifically, the algorithm can (i) enable soft partitioning (one drug can be partitioned into multiple communities with different membership scores); (ii) reduce noise influence (suppresses noise in the high dimensional space); and (iii) allow multi-scale partition. To the best of our knowledge, the algorithm is for the first time used in drug functional network partition.

Specifically, given a weighted undirected network with N nodes, let $\mathbf{V}\operatorname{} \in {\mathbb{R}}_{+}^{\mathbf{N} \times \mathbf{N}}$ denote its adjacent matrix. BNMFβD factorizes the matrix **V** into two low-rank matrices: $$\mathbf{V} \approx \hat{\mathbf{V}} = \mathbf{WH}$$ where **W** and **H** are non-negative matrices with dimensions $N \times K$ and $K \times N$, and the elements of **V**, $\hat{\mathbf{V}}$, ***W*** and ***H*** are denoted by $v_{ij}$, ${\hat{v}}_{ij}$*,*$w_{ik}$ and $h_{kj}$, respectively. The *k*-th column of ***W*** is denoted by $\mathbf{w}_{\mathbf{k}}$ $\in {\mathbb{R}}_{+}^{\mathbf{N} \times \mathbf{K}}$ and the *k*-th row of ***H*** is denoted by $\mathbf{h}_{\mathbf{k}} \in {\mathbb{R}}_{+}^{\mathbf{K} \times \mathbf{N}}$. The ***W*** is normalized to $\mathbf{W}_{\mathbf{N}}$, that is, each row of $\mathbf{W}_{\mathbf{N}}$ is subject to $$\sum\limits_{j = 1}^{K}wn_{ij} = 1$$ where $wn_{ij}$ is the element of $\mathbf{W}_{\mathbf{N}}$ and it quantifies the membership of node *i* with respect to community *j*. To infer the appropriate model order *K*, we use a Bayesian paradigm for non-negative matrix factorization by placing automatic relevance determination priors with scale hyper-parameters $\mathbf{\lambda} = \left\{ \lambda_{k} \right\}_{k = 1}^{K}$ on the variables $w_{ik}$ and $h_{kj}$. In this model, the distribution of $\lambda_{k}$ is parameterized by fixed parameters *a* and *b*, and the fixed parameter β decides the distance measure between the observed interactions $\mathbf{V}$ and the expected interactions $\hat{\mathbf{V}}$. Under these assumptions, the posterior density function can be obtained as $$p\left( {\mathbf{W},\mathbf{H},\mathbf{\lambda}\text{|}\mathbf{V}} \right) = \mathbf{}\frac{p\left( {\mathbf{V}\text{|}\mathbf{W},\mathbf{H}} \right)p\left( {\mathbf{W}\text{|}\mathbf{\lambda}} \right)p\left( {\mathbf{H}\text{|}\mathbf{\lambda}} \right)p(\mathbf{\lambda})}{\mathbf{p}(\mathbf{V})}$$ Maximizing the posterior density is equivalent to minimizing the negative log posterior, which can be regarded as a loss function $C_{MAP}(\mathbf{W},\mathbf{H},\mathbf{\lambda})$ as $$C_{MAP}\left( {\mathbf{W},\mathbf{H},\mathbf{\lambda}} \right) \triangleq - \log p(\mathbf{W},\mathbf{H},\mathbf{\lambda}\text{|}\mathbf{V}\text{)}$$ $$= - \log p\left( {\mathbf{V}\text{|}\mathbf{W},\mathbf{H}} \right) - \log p(\mathbf{W}|\mathbf{\lambda}) - \text{log}\operatorname{}(\mathbf{H}|\mathbf{\lambda}) - \log p(\mathbf{\lambda})$$ where $\log p(\mathbf{V}|\mathbf{W},\mathbf{H})$ is the log-likelihood.

The generalized β-divergence is defined by $$\operatorname{}\operatorname{}\operatorname{}D_{\beta}(x|y) \triangleq \left\{ \begin{matrix}
{\frac{x^{\beta}}{\beta(\beta - 1)} + \frac{x^{\beta}}{\beta} - \frac{xy^{\beta - 1}}{\beta - 1},\operatorname{}\beta \in {\mathbb{R}} \smallsetminus \{ 0,1\}} \\
{x\log\frac{x}{y} - x + y,\beta = 1} \\
{\frac{x}{y} - \log\frac{x}{y} - 1,\operatorname{}\beta = 0} \\
\end{matrix} \right.$$ The β-divergence can be regarded as a minus log-likelihood for the Tweedie distribution and its probability density function is given by $$f\left( {x,\mu,\phi,\beta} \right) = h\left( {x,\phi} \right)\text{exp}\left\{ \frac{1}{\phi}(\frac{1}{\beta - 1}x\mu^{\beta - 1} - \frac{1}{\beta}\mu^{\beta}) \right\}$$ where $h\left( {x,\phi} \right)$ is the base measure function, μ is the mean, ϕ is the dispersion parameter and β is the shape parameter. Assuming that $v_{ij}$ is generated from the Tweedie distribution, the log-likelihood function can be given by $$- \log p(\mathbf{V}\text{|}\mathbf{W},\mathbf{H}\text{)} = \frac{1}{\phi}D_{\beta}\left( {\mathbf{V}\text{|}\mathbf{WH}} \right) + C$$ To insure ***W*** and ***H*** are non-negative, the Half-Normal priors are assigned on them, $$p\left( {w_{ik}\text{|}\lambda_{k}} \right) = \mathcal{H}\mathcal{N}(w_{ik}|\lambda_{k})$$ $$p\left( {h_{kj}\text{|}\lambda_{k}} \right) = \mathcal{H}\mathcal{N}(h_{kj}|\lambda_{k})$$ and place an inverse Gamma priors on each $\lambda_{k}$, $$p\left( {\lambda_{k};a,b} \right) = \frac{b^{a}}{\Gamma(a)}\lambda_{k}^{- (a + 1)}\exp( - \frac{b}{\lambda_{k}})$$ Then, according to [Equation (5)](#btu278-M5){ref-type="disp-formula"}, the objective function $C_{MAP}\left( {\mathbf{W},\mathbf{H},\mathbf{\lambda}} \right)$ can be given as To minimize $C_{MAP}\left( {\mathbf{W},\mathbf{H},\mathbf{\lambda}} \right)$ with respect to ***W***, ***H*** and λ, we adopt the strategy in ([@btu278-B27]) by introducing a local majorization--minimization algorithm with efficient multiplicative updates. Finally, we give the overlapping community detection algorithm as follows: Step 1: Initialize $\mathbf{w}_{\mathbf{k}} \in {\mathbb{R}}_{+}^{\mathbf{N} \times \mathbf{K}}$ and $\mathbf{h}_{\mathbf{k}} \in {\mathbb{R}}_{+}^{\mathbf{K} \times \mathbf{N}}$ to random non-negative values.Step 2: Update ***W***, ***H*** and $\lambda_{k}$ by $$\mathbf{H} = \mathbf{H} \cdot \left( \frac{\mathbf{W}^{T}(\left( \mathbf{WH} \right)^{\cdot {({\mathbf{\beta} - 2})}} \cdot \mathbf{V})}{\mathbf{W}^{T}\left( \mathbf{WH} \right)^{\cdot {({\mathbf{\beta} - 1})}} + \phi/repmat(\mathbf{\lambda},1,N)} \right)^{\cdot \mathbf{\gamma}(\mathbf{\beta})}$$ $$\mathbf{W} = \mathbf{W} \cdot \left( \frac{(\left( \mathbf{WH} \right)^{\cdot {({\mathbf{\beta} - 2})}} \cdot \mathbf{V})\mathbf{H}^{T}}{\left( \mathbf{WH} \right)^{\cdot {({\mathbf{\beta} - 1})}}\mathbf{H}^{T} + \phi/repmat(\mathbf{\lambda},1,N)} \right)^{\cdot \mathbf{\gamma}(\mathbf{\beta})}$$ $$\gamma\left( \beta \right) = \left\{ \begin{matrix}
{1/\left( {3 - \beta} \right),\beta \leq 2} \\
{1/\left( {\beta - 1} \right),\beta > 2} \\
\end{matrix} \right.$$Step 3: Repeat Step 2 until ${\max}_{k = 1,2,\ldots,K}|\left( {\lambda_{k}^{new} - \lambda_{k}^{old}} \right)/\lambda_{k}^{old}| \leq \varepsilon$Step 4: Normalize ***W*** to $\mathbf{W}_{\mathbf{N}}$, then the number of non-zero columns $k^{*}$ of $\mathbf{W}_{\mathbf{N}}$ is the number of clusters. Assign each node to the $k^{*}$ clusters according to $\mathbf{W}_{\mathbf{N}}$. In the above algorithm, $\mathbf{X} \cdot \mathbf{Y}$ denotes element-by-element multiplication of ***X*** and ***Y***; $\frac{\mathbf{X}}{\mathbf{Y}}$ denotes element-by-element division of ***X*** and ***Y***; and $\mathbf{X}^{\cdot \gamma}$ denotes raising each element of ***X*** to the $\gamma^{th}$ power. In addition, $repmat(\mathbf{\lambda},1,N)$ denotes the $K \times N$ matrix with each column being the vectorλ. Using the BNMFβD approach, we partition the drug functional network into a set of connected network modules ([Fig. 2](#btu278-F2){ref-type="fig"}), within which drugs share common targets or related signaling mechanisms.

2.4 Drug combination discovery based on target network analysis {#SEC2.4}
---------------------------------------------------------------

The novel drug combination approach consists of the following three major components.

**(a) Disease specific signaling network reconstruction**

Several approaches ([@btu278-B2]; [@btu278-B4]; [@btu278-B10]) have been proposed to reconstruct signaling networks of diseases based on transcritpome and interactome data. In this study, the approach proposed in ([@btu278-B2]) is used. The integrated protein--protein interactions from BioGRID ([@btu278-B25]) and the manually curated human cancer signaling from ([@btu278-B1]; [@btu278-B6]; [@btu278-B17]; [@btu278-B22]) (available at <http://www.bri.nrc.ca/wang/>) are clustered into functional protein--protein modules, and each module is tested for enrichment (Fisher's exact test, $P < 0.01$) of the differentially expressed genes of the gene expression profile of a disease. The enriched modules are then considered as disease susceptibility modules, from which the highly interconnected genes are identified as the disease-specific signaling network. [Figure 3](#btu278-F3){ref-type="fig"} shows the reconstructed signaling network of lung adenocarcinoma. Fig. 3.The reconstructed signaling network of lung adenocarcinoma. Different node colors indicate different modules, and the node size indicates the degree of nodes

**(b) Functional drug target prediction using network-based recommendation**

Drugs often have multiple targets and affect distinct signaling modules, but only parts of them are known for given drugs. The drug communities embed targeting signaling modules (functional targets instead of physical targets) of drugs. To uncover the targeting signaling modules of drugs, we propose a network-based recommendation approach as follows. Let $D = \left\{ {d_{1},d_{2},\ldots,d_{m}} \right\}$ denote drugs in a given community, and $T = \left\{ {t_{1},t_{2},\ldots,t_{n}} \right\}$ be the known drug targets. The drug--target interaction network can be described as a bipartite graph $G\left( {D,T,E} \right)$. The E indicates the known drug and target associations. This drug--target network can be represented by an adjacent matrix $\mathcal{A} = \left\{ a_{ji} \right\}_{n \times m}$, where $a_{ji}$ is the weight that quantifies the association between $d_{i}$ and $t_{j}$. Then the novel network-based algorithm is designed based on a bipartite network projection technique ([@btu278-B29]) as follows. $$R = F \cdot \mathcal{A}$$ where $R = \left\{ r_{ij} \right\}_{n \times m}$ is the recommendation score (the functional association possibility between drug *i* and target *j*). The $F = \left\{ f_{ij} \right\}_{n \times m}$ indicates the transition matrix from drug *i* to drug *j* and is defined as: $$f_{ij} = \frac{1}{\Gamma\left( {i,j} \right)}\sum\limits_{l = 1}^{m}\frac{a_{il}a_{jl}}{k\left( x_{l} \right)}$$ where $\Gamma\left( {i,j} \right) = k\left( t_{i} \right)^{1 - \lambda}k\left( t_{j} \right)^{\lambda}$ and $k\left( x \right)$ is the degree of the *x* node in the bipartite network. Targets with recommendation scores greater than given threshold, 0.1, are kept as the active functional targets of given drugs.

**(c) Disease-specific drug combination discovery**

With the constructed disease signaling network and the predicted drug targets, drug combinations are then prioritized by combining the following synergistic scores. Given two candidate drugs, $d_{i}$ and $d_{j}$, from different clusters, suppose $d_{i} \in C_{k}$ and $d_{j} \in C_{h}$, and $T_{k} = \left\{ {t_{k1},t_{k2},\ldots,t_{km}} \right\}$ denote the targets of $d_{i}$ in $C_{k}$, and $T_{h} =$ $\left\{ {t_{h1},t_{h2},\ldots,t_{hn}} \right\}$ denote the targets of $d_{j}$ in $C_{h}$. The first synergistic score is defined as follows. $$S_{1}\left( {i,j} \right) = \frac{\sum_{i}CS(t_{ki})\text{exp}\left( {- D\left\{ {t_{ki,}T_{h}} \right\}/n^{2}} \right)}{\sum_{i}CS(t_{ki})}\mspace{63mu} + \frac{\sum_{j}CS(t_{hj})\text{exp}\left( {- D\left\{ {t_{hj},T_{k}} \right\}/m^{2}} \right)}{\sum_{j}CS(t_{hj})}$$ where $CS\left( t_{ki} \right)$ is the centrality score of target $t_{ki}$ in the reconstructed disease signaling network, and it is an additive of betweenness $(Bn)$, closeness $\left( {Cn} \right)$ ([@btu278-B3]) and PageRank (*Pr*) score ([@btu278-B23]) of protein $t_{ki}$, that is $$CS\left( t_{ki} \right) = Bn\left( t_{ki} \right) + Cn\left( t_{ki} \right) + Pr(t_{ki})$$ These are three different but correlated centrality measurements, and the reason of combing them is to get a robust centrality score. The $\min D\left\{ {t_{ki,}T_{h}} \right\}$ is the minimum shortest path from $t_{ki}$ to $T_{h}$. The first synergistic score, $S_{1}\left( {i,j} \right)$, prefers drug combinations, whose targets are in the center (hubs) of disease signaling network and closely connected.

The second synergistic score is defined as $$S_{2}\left( {i,j} \right) = \frac{\sum_{i,j}Sim\left( {t_{ki,}t_{hj}} \right)}{\left( {m + n} \right)\left( {m + n - 1} \right)}$$ where $Sim\left( {t_{ki,}t_{hj}} \right)$ is the semantic similarity of gene ontology (GO) annotations of $t_{ki}$ and $t_{hj}$ ([@btu278-B5]), which is computed based on the overlap of the GO terms that are associated with $t_{ki}$ and $t_{hj}$, and is defined as $$Sim\left( {t_{ki,}t_{hj}} \right) = \frac{2\log_{2}max\left\{ {p\left( A \right)} \right\}}{\left( {\log_{2}p\left( {GO_{ki}} \right) + \log_{2}p\left( {GO_{hj}} \right)} \right)}$$ Where $GO_{ki}$ is the GO term that associated with $t_{ki}$, and *A* is a GO term that is an ancestor of both $GO_{ki}$ and $GO_{hj}$, and $$p\left( {GO_{ki}} \right) = \frac{Freq(GO_{ki})}{MaxFreq}$$ $Freq(GO_{ki})$ is the frequency of GO term $GO_{ki}$ occurring in GO annotations, which are taken from GO database. $MaxFreq$ is the maximum occurrences frequency of GO terms that are associated with all the targets and the predicted drug targets in the GO annotations. The second synergistic score, $S_{2}\left( {i,j} \right)$, prefers drug combinations that block genes with similar functions, e.g. cell proliferation.

Finally, the synergistic score of drug $d_{i}$ and $d_{j}$ is given by $$S_{y}\left( {i,j} \right) = \left( {S_{1}\left( {i,j} \right) + S_{2}\left( {i,j} \right)} \right) \cdot d_{E}(i,j)$$ where $$d_{E}(i,j) = max\left\{ {S_{G}\left( {i,j} \right),\sqrt{S_{G}\left( {i,j} \right) \cdot S_{s}\left( {i,j} \right)},S_{G}\left( {i,j} \right) + S_{s}\left( {i,j} \right)} \right\}$$ where $S_{G}(i,j)$ reflects the distance of their expression pattern. In summary, drug combinations targeting on the disease-specific signaling network, with similar functions, through alternative targets are prioritized.

3 RESULTS
=========

We have applied the BNMFβD algorithm to cluster the drug--drug network into overlapping drug communities. [Table 1](#btu278-T1){ref-type="table"} lists the parameters in the analysis. We set *a* as one of {10,50,100,150,200,250,300,350,400,450}, and *b* to be equal to *a*. When *a* and *b* are set to be 450, the BNMFβD algorithm will converge more quickly. Under this setting of *a* and *b*, we test the drug network community reconstruction results with different *K* and β, as K = {100,110,120,130,140,150,160,170} and $\beta = \left\{ 1,2 \right\}$. When *K* is 150 and β is 1, we get better drug community structures in terms of the following defined community quality measurements. We assign the number from 1 to 150 to each drug community, and obtain the drug--target networks by connecting the drugs in the same community through their targets. The connected drug--target networks provide us a useful way to drug discovery. Table 1.The values of parameters in BNMFβD algorithmParametersValues*K*150β1*a* = *b*450**ε**10^−5^

3.1 Quality evaluation of predicted drug community {#SEC3.1}
--------------------------------------------------

To evaluate the proposed approach, we compared it with three widely used network partition approaches: Markov cluster (MCL; [@btu278-B8]), affinity propagation (AP; [@btu278-B9]) and CluterONE ([@btu278-B21]). To evaluate the quality of the predicted drug community, the following three metrics are defined. The average enrichment score, $S_{N}$, is defined as $S_{N} = \frac{\sum_{i = 1}^{N}s_{i}N_{i}}{\sum_{i = 1}^{N}N_{i}},$where $s_{i} = \frac{P_{i}}{N_{i}}$, *P~i~* is the number of drug pairs sharing targets in the *i*-th drug community, $N_{i}$ is the number of drugs of that drug community and *N* is the number of drug community. Higher $S_{N}$ value indicates more drugs in the same community sharing common targets. The metric, $S_{R}$, is defined as the relative number of well-connected drug communities $S_{R} = \frac{\left| \left\{ {s_{i}\text{|}s_{i} > d} \right\} \right|}{N}$, where \|.\| is the number of elements, and *d* is a given threshold. The geometric accuracy metric, $S_{GA}$, is defined as the balance of the two metrics: $S_{GA} = \sqrt{S_{N} \cdot S_{R}}$. The comparison result shown in [Figure 4](#btu278-F4){ref-type="fig"} shows that the proposed method outperforms the other three methods in terms of all three metrics with $d = 0.6$. Fig. 4.The comparison results of the proposed method (referred to as BNMF βD) with AP, ClusterONE and MCL according to the quality of the predicted drug communities in terms of *S*~N~, *S*~R~ and *S*~GA~

3.2 Drug combination prediction evaluation {#SEC3.2}
------------------------------------------

To evaluate the prediction capacity of DrugComboRanker, we apply it on the lung adenocarcinoma and endocrine receptor (ER) positive breast cancer. The 107 lung adenocarcinoma patient samples (58 lung tumor tissues and 49 normal lung tissues, GDS3257) were collected to reconstruct the lung adenocarcinoma-specific signaling network, as shown in [Figure 3](#btu278-F3){ref-type="fig"}. This signaling network consists of 905 genes and 11 282 interactions. Based on the signaling network, we predict effective drugs that have synergistic effects combined with three drugs (Gefitinib, Paclitaxel and LY-294002) given by our clinicians. Level 3 gene expression data of 222 ER positive breast invasive carcinoma (BRCA) samples and 61 normal breast samples were collected from TCGA. The synergistic drug combination with two FDA-approved drugs, Tamoxifen and Letrozole, are further predicted for ER-positive BRCA based on the reconstructed ER-positive breast cancer signaling network.

To validate the prediction results, we searched the literature evidence of the top 50 ranked combinations. [Tables 2--4](#btu278-T2 btu278-T3 btu278-T4){ref-type="table"} show the literature evidence of the effective drug combinations in our top 50 lists for lung adenocarcinoma. Surprisingly, 19 different drug combinations have been reported to be synergistic combining with Gefitinib, Paclitaxel and LY-294002 in non--small-cell lung cancer. [Tables 5](#btu278-T5){ref-type="table"} and [6](#btu278-T6){ref-type="table"} show the literature evidence of effective drug combinations in the top 50 lists for ER-positive breast cancer. Also 14 different drug combinations have been reported to be synergistic combining with Tamoxifen and Letrozole. These results show the strong drug combination prediction capacity of DrugComboRanker. Table 2.Synergistic alternative drugs combining with GefitinibDrug combination (Community number)Synergistic scoreRankLiterature evidenceGefitinib/Paclitaxel (63/55)2.905 2PMID:19596955PMID:14990633Gefitinib/Celecoxib (63/48)2.804 3PMID:18379355PMID:16914589Gefitinib/Genistein (63/102)2.765 4PMID:22160570Gefitinib/Fulvestrant (63/55)2.529 9PMID:24268810Gefitinib/Irinotecan (63/66)2.46811PMID:21915126PMID:16713012Gefitinib/Vorinostat (63/102)2.46412PMID:21271222Gefitinib/Lovastatin (63/34)2.10227PMID:19760159Gefitinib/Rosiglitazome (63/13)2.02332PMID:168386327Gefitinib/MS-275(63/102)2.00734PMID:16424029 Table 3.Synergistic alternative drugs combining with LY-294002Drug combination (Community number)Synergistic scoreRankLiterature evidenceLY-294002/Quercetin (55/140)2.987 2PMID:14688022LY-294002/SB-202190(55/5)2.936 3PMID:16115952LY-294002/Rapamycin(55/54)2.44833PMID:22355375 Table 4.Synergistic alternative drugs combining with PaclitaxelDrug combination (Community number)Synergistic scoreRankLiterature evidencePaclitaxel/Irinotecan(55/66)3.096 2PMID:16251879Paclitaxel/Gefitinib(55/63)2.905 8PMID:19596955PMID:14990633Paclitaxel/Vorinostat(55/102)2.901 9PMID:19621389Paclitaxel/Rapamycin(55/54)2.88811PMID:22896668Paclitaxel/Vinblastine(55/137)2.68117PMID:16193638Paclitaxel/Ifosfamide(55/90)2.37725PMID:8740798Paclitaxel/SuraminSodium (55/3)2.18937PMID:11507065Paclitaxel/Resveratrol(55/48)2.06049PMID:14666716 Table 5.Synergistic alternative drugs combining with TamoxifenDrug combination (Community number)Synergistic scoreRankLiterature evidenceTamoxifen/Tretinoin(49/55)2.913 8PMID:9533531Tamoxifen/Genistein(49/102)2.910 9PMID:17295235Tamoxifen/Quercetin(49/140)2.83112PMID:20804812Tamoxifen/Verapamil(49/66)2.77619PMID:8185686Tamoxifen/Mifepristone(49/66)2.72121PMID:9879777Tamoxifen/Celecoxib(49/48)2.43729PMID:23731702Tamoxifen/Resveratrol(49/48)2.41631PMID:23896596Tamoxifen/Letrozole(49/92)2.29936PMID:15026471Tamoxifen/Exemestane(49/51)2.13642PMID:21247627Tamoxifen/LY-294002(49/55)2.03546PMID:12479367 Table 6.Synergistic alternative drugs combining with LetrozoleDrug combination (Community number)Synergistic scoreRankLiterature evidenceLetrozole/Fulvestrant(92/55)2.457 8PMID:15958593Letrozole/Tamoxifen(92/49)2.30010PMID:15026471Letrozole/Metformin(92/56)2.14815NCT01589367Letrozole/Celecoxib(92/48)2.12816PMID:19254941Letrozole/Imatinib(92/55)1.76540NCT00338728

To make the evaluation fair and sound, we further compared the predicted results with CDA, and a random combination method (RCM), which randomly picks up 50 drugs from the available drug lists to combine with the designated drugs. As for CDA, we picked the top 50 drug combinations with the designated drugs. [Figures 5](#btu278-F5){ref-type="fig"} and [6](#btu278-F6){ref-type="fig"} show the comparison results on the lung adenocarcinoma and ER-positive breast cancer in terms of literature supports of those top-ranked 50 drug combinations, respectively (The numbers on the bars of RCM are standard deviations). For RCM, we repeated the random selection 100 times; for each simulation, we checked the literature evidence (In total, we checked all the 5000 random combinations). As can be seen, the proposed approach outperforms the CDA and random selection significantly. Fig. 5.The comparison results of DrugComboRanker, CDA and RCM in terms of the number of literature supports of the top-ranked 50 drug combinations of lung adenocarcinoma with designated drugs, Gefitinib, Paclitaxel and LY-294002 Fig. 6.The comparison results of DrugComboRanker, CDA and RCM in terms of the number of literature supports of the top-ranked 50 drug combinations of ER-positive breast cancer with designated drugs, Tamoxifen and Letrozole

The predicted drug targets in the disease-specific network could indicate the molecular mechanism of synergistic drug combinations. Here, we map the responsive genes of Gefitinib, Paclitaxel, Vorinostat, LY-294002 and Quercetin to the lung adenocarcinoma-specific signaling network to capture the distinct synergistic responses induced by three agent combinations, Gefitinib and Paclitaxel, LY-294002 and Quercetin, Gefitinib and Vorinostat. As shown in [Figure 7](#btu278-F7){ref-type="fig"}, Gefitinib and Paclitaxel combinations can affect the EGFR signaling pathway (endothelial cell proliferation), TP53 signaling pathways, as well as biological processes, such as cell cycle, apoptosis and the hub genes, i.e. EGFR, TP53, SRC, FOS, JUN. Distinctly the LY-294002 and Quercetin combination affects the alternative EGFR, PI3K-AKT and JAK-STAT3 pathways, as can be seen in [Figure 8](#btu278-F8){ref-type="fig"}. In addition, the drug combination, Gefitinib and Celecoxib, targets the EGFR and COX-2 signaling pathways, respectively. The Gefitinib and Celecoxib have distinct transcriptional responses that indicate EGFR and COX-2 signaling pathways are complementary, and have cross talks. Another example is Gefitinib and Vorinostat combination. Vorinostat is a Histone deacetylases inhibitor, as shown in [Figure 9](#btu278-F9){ref-type="fig"}, which interacts with CTNNB1, and CTNNB1 interacts with E-cadherin, ERBB2 and EGFR, whereas Gefitinib targets on EGFR. Thus, this combination forms a double inhibition on growth factors. Fig. 7.Drug targets mapped on the disease signaling network. Red and green are the drug targets of Gefitinib and Paclitaxel, respectively Fig. 8.Drug targets mapped on the disease signaling network. Red and green are the drug targets of LY-294002 and Quercetin, respectively; blue nodes are the weak effected targets of both drugs Fig. 9.Drug targets mapped on the disease signaling network. Red and green are the drug targets of Gefitinib and Vorinostat, respectively

4 DISCUSSION AND CONCLUSION
===========================

Drug combinations can provide an optimal cancer therapeutic treatment by overcoming acquired drug resistance. Clinicians usually choose drug combinations manually based on their experience and expertise. However, this expert-picking-based method cannot be scaled up for discovering drug combinations from a large set of drugs. The availability of genomic profiles of drugs and patients are informative for uncovering the regulatory signaling networks of cancers and the mechanisms of action of drugs. However, the computational tools are the bottleneck to interpret and convert the big genomics data into discovery of drug combinations. In this study, we propose a novel computational tool, DrugComboRanker, to prioritize drug combinations for specific cancers by selecting combinations targeting the alternative and complementary signaling modules of disease. We first predict the functional targets of drugs via the network community analysis of drug functional networks based on their genomic profiles. We then define the synergistic score of drug combinations that block key disease genes and their potential cross talks. The new method can also provide insights into mechanism of actions of drug combinations by mapping the predicted drug targets on the disease signaling network. In our case studies on lung adenocarcinoma and ER-positive breast cancer cases, a set of top-ranked drug combinations, with similar and distinct mechanisms of action, top-ranked in our prediction list have been reported to be effective in anticancer treatment. Moreover, a set of novel drug combinations are also identified with a better anticancer treatment outcome. In conclusion, the DrugComboRanker has the potential to be a widely used software package for predicting new disease-specific drug combinations.
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